Haemodialysis catheter-related bloodstream infections: Current treatment options and strategies for prevention

Swiss Medical Weekly

Volumn 135, Issue 9-10, 2005, Pages 127-138

  Saxena, Anil K ^a,b   Panhotra, Bodh R ^a  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

CRBSI; Epidemiology; Haemodialysis; Preventive strategies; Treatment options

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE; CIPROFLOXACIN; GENTAMICIN; HYPOCHLORITE SODIUM; MINOCYCLINE; NEOMYCIN; POLYMYXIN; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN; SULFADIAZINE SILVER; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTERIOVENOUS FISTULA; BACTERIAL ENDOCARDITIS; CATHETER; CATHETER INFECTION; CENTRAL VENOUS CATHETER; GUIDE WIRE; HEMODIALYSIS; HUMAN; INFECTION CONTROL; INFECTION RISK; OTOTOXICITY; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; VASCULAR ACCESS;

EID: 16244418378     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. United States Renal Data System 1999 Annual Data Report: part IX. Hospitalization in ESRD. Am J Kidney Dis 1999;34:114-23.
2. Burr R, Marszalek J, Saul M, Shields M, Aslam N. The cost of vascular access infections: three years experience from a single outpatient dialysis center. Hemodial Int 2003;7:73-104.
3. Liu JW, Su YK, Liu CP, Chen JB. Nosocomial blood-stream infections in patients with end-stage renal disease; excess length of hospital stay, extra cost and attributed mortality. Hosp Infect 2002;50:224-7.
4. United States Renal Data System 1999 Annual Data Report: part VI. Causes of death. Am J Kidney Dis 1999;34:87-94.
5. Butterly DW, Schwab SJ. Dialysis access infections. Curr Opin Nephrol Hypertens 2000;9:631-5.
6. Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol Dial Transplant 1999;14:1710-4.
7. Oliver MJ, Gallery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int 2000;58:2543-45.
8. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999;34:1114-24.
9. Cheesbrough JS, Finch RG, Burden RP. A prospective study of mechanisms of infection associated with hemodialysis catheters. J Infect Dis 1986;154:579-89.
10. De Cicco M, Campisi C, Matovic M. Central venous catheter-related bloodstream infections: Pathogenesis factors, new perspectives in prevention and early diagnosis. J Vasc Access 2003; 4:83-91.
11. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
12. Foster TJ, McDevitt D. Surface-associated proteins of Staphylococcus aureus: their possible roles in virulence. FEMS Microbiol 1994;118:199-205.
13. Patti JM, Allen BE, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994;48:585-617.
14. Farber BF, Kaplan MH, Clogstron AG. Staphylococcus epidermidis extracted slime inhibits antimicrobial action of glycopeptide antibiotics. J Infect Dis. 1990;161:37-40.
15. Adeniyi OA, Tzamaloukas. Relation between access-related infection and pre-infection serum albumin concentration in patients on chronic hemodialysis. Hemodial Int 2003;7:304-10.
16. Descamps-Latscha B, Drúeke T, Witko-Sarat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001;14:193-9.
17. Pecoits-Filho R, Landholm B, Stenvinkel P. The malnutrition, inflammation and atherosclerosis (MIA) syndrome. Nephrol Dial Transplant 2002;17:28-31.
18. Descamps-Latscha B, Jungers P, Witko-Sarat V. Immune system dysregulation in uremia: Role of oxidative stress. Blood Purific. 2002;20:481-4.
19. Meier P, Payer E, Blanc E, et al. Early T-cell activation correlation with expression of apoptosis markers in patients with end stage renal disease. J am Soc Nephrol 2002;13:204-12.
20. Lee LY, Miyamoto YJ, McIntyre BW, et al. The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell-mediated responses. J Clin Invest 2002;110:1461-71.
21. Ashwani RS, Mercia RS, Kenneth EC, Richard C, Jeanette AC. Use of standardarized ratios to examine viability in haemodialysis vascular access across facilities. Am J Kidney Dis 2000;35: 275-81.
22. Jaar BG, Herman JA, Furth SE, Briggs W, Powe NR. Septicemia in diabetic haemodialysis patients: Comparison of incidence, risk factors and mortality with non-diabetic patients. Am J Kidney Dis 2000;35:282-92.
23. Munshi SK, Narayanaswami VK, Nicholas AT, Harneeta B, Nelson TC, Graham W. Outcome of renal replacement therapy in the very elderly. Nephrol Dial Transplan 2001;16: 128-33.
24. Saxena AK, Panhotra BR, Chopra R. Advancing age and risk of nasal carriage of Staphylococcus aureus among patients on long-term hospital-based hemodialysis. Ann Saudi Med 2004;24: 337-42.
25. Saxena AK, Panhotra BR, Venkateshappa CK, Wahid U. The role of Staphylococcus aureus nasal carriage and the type of vascular access in the outcome of high-risk patients on hemodialysis. J Vasc Access 2002;3:74-9.
26. Saxena AK, Panhotra BR. The prevalence of nasal carriage of Staphylococcus aureus and associated vascular access-related septicemia among patients on hemodialysis in Al-Hasa region of Saudi Arabia. Saudi J Kidney Dis Transplant 2003;14:30-8.
27. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001;344:11-6.
28. Saxena AK, Panhotra BR, Wahid Uzzaman. The impact of nasal carriage of Staphylococcus aureus on the type of vascular access and dialysis access-related septicemia in elderly. Dial Transplant 2003;32:2-10.
29. Kaptowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. Prospective study of microbial colonization of nose and skin and infection of vascular access site in hemodialysis patients. J Clin Microbiol 1988;26:1257-62.
30. Ballerini L, Conte F, Paris V. Gruppo Italiano Multidisciplinare Educazione Predialisi Baxter. Early or late referral patterns of 1137 patients starting dialysis in 15 Italian dialysis centres. G Ital Neurol 2002;19:419-24.
31. Thomas-Hawkins C. Nursing interventions related to vascular access infections. Adv Ren Replace Ther 1996;3:218-21.
32. Robinson DL, Fowler WG, Saxton DJ, et al. Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis 1997;30: 521-4.
33. Kovalik EC, Raymond JR, Albers FJ, et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in case of infection. J Am Soc Nephrol 1996;7:2264-7.
34. Mohamed M, Habte-Gabr E, Mueller W. Infected arteriovenous hemodialysis graft presenting as left and right infective endocarditis. Am J Nephrol 1995;15:521-3.
35. Marr KA, Saxton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter related bacteremia and outcome attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997;127:275-80.
36. Marr KA, Kong LK, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998;54:1684-9.
37. Chang CF, Kuo BIT, Chen TL, Yang WC, Lee SD, Lin CC. Infective endocarditis in maintenance hemodialysis patients: Fifteen years' experience in one medical center. J Nephrol 2004;17:228-35.
38. Fowler WG, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience of 103 patients. J Am Coll Cardiol 1997; 30:1072-8.
39. Saxena AK, Panhotra BR, Naguib M, et al. Septicemia in hemodialysis: A focus on bacterial flora and antibiotic access salvage. Saudi J Kidney Dis Transplant 2002;13:29-34.
40. NKF-DOQI Clinical Practice Guidelines for vascular access update, 2000, National Kidney Foundation, New York, New York. Guideline 26:25-28.
41. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992;14:75-82.
42. Lemus J, Parra H, Undurraga A. antibiotic management of infected vascular access. Nephrol Dial Transplant 2001;16: 1521-2.
43. Saad TF. Central venous dialysis catheters: catheter-associated infection. Semin Dial 2001;14:446-51.
44. Bastani B, Minton J, Islam S. Insufficient penetration of systemic vancomycin into the PermCath lumen. Nephrol Dial Transplant 2000;15:1035-7.
45. Shaffer D. Catheter-related sepsis complicating long-term tunneled central venous dialysis catheters: management by guide wire exchange. Am J Kidney dis 1995;25:593-6.
46. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999; 10:1045-9.
47. Tanriover B, Carlton D, Saddekni S, et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int 2000;57:2151-5.
48. Pearson ML, for the Hospital Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular device-related infections Part I and II. Am J Infect Control 1996;24:262-93.
49. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997;30:50-91.
50. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: A new approach to optimal therapy for catheter related sepsis in home patenteral nutrition patients. J Enteral Parenteral Nutr 1988;12:185-9.
51. Sodermann K, Lubrich-Bricker I, Berger O, Beumert J, Feldmer B, Van Hodenberg E. Gentamicin/sodium citrate mixture as antibiotic lock technique for salvage and prevention of catheter-related infections- a four year trial [Abstract]. J Am Soc Nephrol 1997;8:173A.
52. Capdevila JA, Segarra A, Planes AM. Successful treatment of haemodialysis catheter related sepsis without catheter removal. Nephrol Dial Transplant 1993;8:231-4.
53. Krishnaswami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with adjunctive antibiotic lock solution. Kidney Int 2002;61:1136-42.
54. Vercaigne LM, Zelenitsky SA, Findlay I Burnstein K, Penner SB. An in-vitro evaluation of the antibiotic/heparin locks to sterilize central venous hemodialysis catheters. J Antimicrob Chemother 2002;49:693-6.
55. Vercaigne LM, Sitar DS, Penner SB, Bernstein K, Wang GQ, Burczynski FJ. Antibiotic-Heparin lock: In vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 2000;20:394-9.
56. Saxena AK, Panhotra BR, Naguib M. Sudden irreversible sensory-neural hearing loss in a diabetic on hemodialysis, receiving amikacin as antibiotic-heparin lock. Pharmacotherapy 2002; 22:105-8.
57. Saxena AK. Ototoxicity from the aminoglycosides-heparin/citrate locks applied for the prevention for the prevention of hemodialysis catheter-related infections. J Vasc Access 2003;4: 35-6.
58. Berrington A, Gould FK. Use of antibiotic locks to treat colonized central venous catheters. J Antimicrob Chemother 2001; 48:597-603.
59. Bailey E, Berry N, Cheesbrough JS. Antimicrobial lock therapy for catheter-related bacteremia among patients on maintenance haemodialysis. J Antimicrob Chemother 2002;50:611-8.
60. Poole C V, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol-effect of bacterial pathogen. Nephrol Dial Transplant 2004; 19: 1237-44.
61. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004;66:801-5.
62. Raad II, Hohn DC, Gilbreth BY, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994;15:231-8.
63. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone - iodine, alcohol and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991;338:339-43.
64. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int 1991;40:934-48.
65. Maki DG, Band JD. Comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am J Med 1981;70:739-44.
66. Maki DG, Mermel L. Meta-analysis of transparent vs. gauze dressing for central venous catheter use. Infect Control Hosp Epidemiol 1997;18(Suppl 2):51-6.
67. Silverberg D, Stozenko F, Blum M, et al. Mupirocin ointment application at exit site of temporary central line hemodialysis catheters markedly reduces S. aureus bloodstream infections. Dial Transplant 2003;32:484-9.
68. Johnson DW, Mac Ginley R, Kay TD, et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002;17:1802-7.
69. Rao SP, Oreopoulos DG. Unusual complications of polyurethane PD catheter. Peri Dial Int 1997;17:410-2.
70. Riu S, Ruiz CG, Martinez-Vera A, Peralta C, Oliver JA. Spontaneous rupture of polyurethane peritoneal catheter: a possible deleterious effect of mupirocin ointment. Nephrol Dial Transplant 1998;13:1870-1.
71. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBAC-DIAL: a multicenter prospective study of risk factors of bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-87.
72. Goetz AM, Wagener MM, Miller JM, Muder RR. Risk of infection due to central venous catheter: effect of site of placement and catheter type. Infect Control Hosp Epidemiol 1998; 19:842-5.
73. Viale P, Politi E, Sisti M, Confalonieri M, Alberici F. Impact of central venous catheters (CVC) management on infectious risk. J Hosp Infection 1998;40(Suppl A):8.1.8.
74. Trottier SJ, Verimakis C, O'Brian J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from prospective randomized trial. Crit Care Med 1995; 23:52-9.
75. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteremias in hemodialysis patients. Nephrol Dial Transplant 1993;8:235-9.
76. Kluytmans JA, Manders MJ, Van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hospital Epidemiol 1996; 17:793-7.
77. McAnally TP, Lewis MR, Brown DR. Effect of rifampicin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother 1984;25:422-6.
78. Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Furumoto A. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect 2001;47: 294-300.
79. Sands J, Miranda CL. Increasing numbers of AV fistulas for hemodialysis access. Clin Nephrol 1997;48:114-7.
80. Konner K. Increasing the proportion of diabetics with AV fistulas. Semin Dial 2001;14:1-4.
81. Saxena AK, Panhotra BR, Naguib M, et al. The impact of achieving goal for AV fistula set by NKF-DOQI, on Staphylococcus aureus septicemia. Dial Transplant 2002;31:16-23.
82. Saxena AK, Panhotra BR, Naguib M, Sundaram DS, Venkateshappa CK, Uzzaman W, et al. Outcome of Dialysis access-related septicemia among diabetics following optimized AV-fistula placement. Kidney Blood Press Res 2002;25:109-14.
83. Maid DG, Stoltz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled study. Ann Intern Med 1997;127:157-66.
84. Ciresi D, Albrecht RM, Volkers PA, Scholten DJ. Failure of an antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am Surg 1996;62:641-6.
85. Heard SO, Wagle M, Vijayakumar K, et al. The influence of tripple lumen central venous catheters coated with chlorhexidine and silver sulphadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 1998;158:81-7.
86. Raad I, Darouiche R, Hachem R, et al. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampicin. J Infect Dis 1996;173:418-24.
87. Raad I, Darouiche R, Hachem R, et al. antibiotics and prevention of microbial colonization of catheters. Antimicrob agents Chemother 1995;39:2397-400.
88. Darouich RO, Raad II, Heard SO, et al. A comparison of two antimicrobial - impregnated central venous catheters. N Eng J Med 1999;340:1-8.
89. Raad I, Darouiche R, Hachem R, et al. Antimicrobial durability and rare ultrastructural colonization of indwelling central venous catheters coated with minocycline and rifampicin. Crit Care Med 1998;26:219-24.
90. Bambauer R, Latza R, Bambauer S, Tobin E. Large bore catheters with surface treatments versus untreated catheters for vascular access in hemodialysis Artificial Organs 2004;28: 604-10.
91. Bleyer A, Mason L, Raad I, Sherertz R. A randomized double blind trial comparing minocycline/EDTA with heparin as flush solutions for hemodialysis catheters. Program and abstracts of 4th Decennial Conference Program committee. March 5-9, 2000; Atlanta, GA. (Abstract P-S 1-31).
92. Carratala J, Niubo J, Fernandez-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999;43:2200-4.
93. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling of gentamicin and citrate: A randomized control study. J Am Soc Nephrol 2002;13:2133-9.
94. Pervez A, Ahmad M, Ram S, et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated with bacteremia. J Vasc Access 2002;3:108-13.
95. FDA Issues Warning on Tricitrasol Dialysis Catheter Anticoagulant [Internet]. FDA Talk Paper. Rockville, MD: Food and Drug Administration, U.S. Department of Health and Human Services, Public Health Service, 2000 Apr 14. Available from: www.fda.gov/bbs/topics/ANSWERS/ANS01009.html
96. Saxena AK, Panhotra BR, Al-Ghaindi AMA. Antibiotic-heparin lock technique: A potentially precious tool to prevent hemodialysis catheter-related septicemia. Saudi J Kidney Dis Transplant 2004;15:67-70.
97. Francisco IL, Mercedes P, Pedro O, Rafel S, Enrique C. Cefotaxime, twenty years later; Observational study in critically ill patients. Enferm Infecc Microbiol Clin 2001;19:211-8.
98. Moore HL, Twardowski ZJ. The air-bubble method of locking central vein catheters with acidified concentrated sodium chloride as a bactericidal agent: in-vitro studies. Hemodial Int 2003;7:311-9.
99. Twardowski ZJ, Reams G, Prowant BF, Moore HL, Van Stone JC. Air-bubble method of locking central-vein catheters for prevention of hub colonization: a pilot study. Hemodial Int 2003;7:320-5.
100. Appelgren P, Ransjo U, Bindslev L, Esperson F, Larm O. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective randomized trial. Crit Care Med 1996;24:1482-9.
101. Liu WK, Tebbs SE, Byrne PO, Elliot TS. Effects of electric current on bacteria colonizing intravenous catheter. J Infect 1993;27:261-9.
102. Raad I, Hachem R, Zermano A, Stephens LC, Bodey GP. Silver iontophoretic catheter: a prototype of a long-term anti-infective vascular access device. J Infect Dis 1996;173:495-8.
103. Vaudaux P, Pittet D, Haeberli A, Lerch PG, Morganthaler J-J, Proctor RA, et al. Fibronectin is more active than fibrin or fibrinogen in promoting Staphylococcus aureus adherence to inserted intravascular catheters. J Infect Dis 1993;167:633-41.
104. Huesca M, Sun Q, Peralta R, Sauder DN, McGavin MJ. Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibronectin-binding protein, which are composed of amino acids that are essential for fibronectin binding. Infect Immun 2000;68:1156-63.
105. Sun Q, Smith GM, Zahradka C, McGavin MJ. Identification of D motif epitopes in Staphylococcus aureus fibronectin-binding protein for the production of antibody inhibitors of fibronectin binding. Infect Immun 1997;65:537-43.
106. Davies DG, Parsec MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998;280: 295-8.
107. Parsek MR, Val DL, Hanzelka BL, Cronan JE, Greenberg EP. Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA 1999;96:4360-5.
108. Otto M, Sussmuth R, Vuong C, Jung G, Gotz F. Inhibition of virulence factor expression in Staphylococcus aureus by the Staphylococcus epidermidis agr pheromone and derivative. FEBS Lett 1999;450:257-62.
109. Ziebuhr W, Heilmann C, Gotz F, et al. Detection of the intercellular gene cluster (ica) and phase variation in S. epidermidis blood culture strains and mucosal isolates. Infect Immun 1997;65:890-6.